Nurix-Roche $2.3B BTK Degrader Deal Clears Antitrust Hurdle
NRIX has more than doubled off its 52-week low of $8.195.
Summary
The Hart-Scott-Rodino waiting period expired, clearing the last major regulatory hurdle for the Nurix-Roche collaboration announced June 8. The deal includes a $700M upfront payment, up to $2.3B in milestones, and a 40/60 cost split. With antitrust clearance, the partnership can now close, bringing Nurix's pro-forma cash to ~$1.14B and derisking the bexobrutideg program. The collaboration spans CLL, B-cell malignancies, MS, and CSU, with Roche leading ex-U.S. commercialization. This follows the June 11 positive Phase 1b data and Q2 earnings showing a $443.5M cash position. The clearance removes uncertainty and allows the companies to advance the Phase 2 trial.
At the time of this announcement, NRIX was trading at $23.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $8.20 to $25.09. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.